(Q46452729)

English

High concordance between HercepTest immunohistochemistry and ERBB2 fluorescence in situ hybridization before and after implementation of American Society of Clinical Oncology/College of American Pathology 2007 guidelines

scientific article published on 15 June 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/22699517

High concordance between HercepTest immunohistochemistry and ERBB2 fluorescence in situ hybridization before and after implementation of American Society of Clinical Oncology/College of American Pathology 2007 guidelines (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/22699517

0 references

immunohistochemistry

1 reference

based on heuristic

inferred from title

Erb-b2 receptor tyrosine kinase 2

1 reference

based on heuristic

inferred from title

author name string

Maria E Vergara-Lluri

1

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/22699517

Neda A Moatamed

2

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/22699517

Elizabeth Hong

3

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/22699517

Sophia K Apple

4

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/22699517

publication date

15 June 2012

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/22699517

Modern Pathology

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/22699517

25

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/22699517

10

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/22699517

1326-1332

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/22699517

https://scigraph.springernature.com/pub.10.1038/modpathol.2012.93

0 references

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.93

21 January 2018

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.93

21 January 2018

Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.93

21 January 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.93

21 January 2018

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.93

21 January 2018

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.93

21 January 2018

Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.93

21 January 2018

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.93

21 January 2018

HER-2 testing in breast cancer using parallel tissue-based methods

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.93

21 January 2018

HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.93

21 January 2018

Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.93

21 January 2018

Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.93

21 January 2018

Dynamic and modern: bringing the ethics of phase I trials up to date.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.93

21 January 2018

Effect of ischemic time, fixation time, and fixative type on HER2/neu immunohistochemical and fluorescence in situ hybridization results in breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.93

21 January 2018

Effects of the change in cutoff values for human epidermal growth factor receptor 2 status by immunohistochemistry and fluorescence in situ hybridization: a study comparing conventional brightfield microscopy, image analysis-assisted microscopy, and

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.93

21 January 2018

Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.93

21 January 2018

Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.93

21 January 2018

Saving lives with accurate HER2 testing.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.93

21 January 2018

Achieving 95% cross-methodological concordance in HER2 testing: causes and implications of discordant cases.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.93

21 January 2018

High Concordance Between Two Companion Diagnostics Tests

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.93

21 January 2018

The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.93

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.93

7 January 2021

based on heuristic

inferred from DOI database lookup

HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.93

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of delay in fixation, different fixatives, and duration of fixation in estrogen and progesterone receptor results in breast carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.93

7 January 2021

based on heuristic

inferred from DOI database lookup

Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.93

7 January 2021

based on heuristic

inferred from DOI database lookup

Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.93

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/MODPATHOL.2012.93

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/22699517

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/22699517

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46452729&oldid=2112414339"